2. Academic Validation
  3. Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors

Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors

  • J Med Chem. 2010 Aug 12;53(15):5639-55. doi: 10.1021/jm100383b.
Alfonso Zambon 1,  Delphine Ménard,  Bart M J M Suijkerbuijk,  Ion Niculescu-Duvaz,  Steven Whittaker,  Dan Niculescu-Duvaz,  Arnaud Nourry,  Lawrence Davies,  Helen A Manne,  Filipa Lopes,  Natasha Preece,  Douglas Hedley,  Lesley M Ogilvie,  Ruth Kirk,  Richard Marais,  Caroline J Springer
Affiliations

Affiliation

  • 1 The Institute of Cancer Research, Cancer Research UK Centre for Cancer Therapeutics, Sutton, Surrey, UK.
PMID: 20597484 DOI: 10.1021/jm100383b
Abstract

Mutated BRAF serine/threonine kinase is implicated in several types of Cancer, with particularly high frequency in melanoma and colorectal carcinoma. We recently reported on the development of BRAF inhibitors based on a tripartite A-B-C system featuring an imidazo[4,5]pyridin-2-one group hinge binder. Here we present the design, synthesis, and optimization of a new series of inhibitors with a different A-B-C system that has been modified by the introduction of a range of novel hinge Binders (A ring). The optimization of the hinge binding moiety has enabled the development of compounds with low nanomolar potencies in both BRAF inhibition and cellular assays. These compounds display optimal pharmacokinetic properties that warrant further in vivo investigations.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z